blood-test
(6)
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
Karius
Karius is a Redwood City, California life-sciences company that turns a single blood draw into a broad infectious-disease diagnosis. Its flagship Karius Test uses microbial cell-free DNA (mcfDNA) sequencing, metagenomics and AI to detect more than 1,000 pathogens - bacteria, DNA viruses, fungi and parasites - often within a day of receiving a sample. Founded in 2014 out of Stephen Quake's lab at Stanford, the company aims to give clinicians a fast, non-invasive alternative to invasive biopsies and slow cultures, with a focus on the immunocompromised patients who need answers most urgently.
Aqtual, Inc.
Aqtual, Inc. is a Hayward, California precision medicine company that reads epigenetics, gene regulation and transcriptomics from a single blood draw. Its proprietary active-chromatin cell-free DNA (cfDNA) platform captures circulating chromatin to survey hundreds of thousands of regulatory sites, integrating DNA, epigenetic regulation and protein-DNA binding in one blood-based assay. The company is first commercializing a test that predicts which therapy will work for rheumatoid arthritis patients, with a broader pipeline spanning oncology, immunology, cardiovascular, metabolic and neurological disease. Aqtual has raised roughly $47M to date, including a $31M Series B in July 2025.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
Mirvie
Mirvie is a South San Francisco biotech using cell-free RNA signatures and machine learning to predict pregnancy complications - preeclampsia, preterm birth, fetal growth restriction - months before symptoms appear. Its flagship product Encompass is a blood test built on a foundational study of nearly 11,000 pregnancies.
AltPep
AltPep is a Seattle biotech company spun out of the University of Washington that is building both diagnostic tests and disease-modifying drugs for amyloid diseases such as Alzheimer's and Parkinson's. Its work is anchored on the alpha-sheet, a non-standard protein structure discovered by founder and CEO Valerie Daggett, which forms in the toxic soluble oligomers that appear at the earliest, pre-symptomatic stages of disease. AltPep's SOBA blood test aims to flag those toxic oligomers years before symptoms, while its SOBIN peptide therapeutics are designed to neutralize them.